Ketamine Clinical Trials
Effects of Ketamine Treatment on Suicidal Ideation, Drug-resistant Major Depression, and Negative Emotional Experience. Clinical and fMRI Study
To see complete record on clinicaltrials.gov, please visit this link
Id: NCT02037503
Organisation Name: Tel-Aviv Sourasky Medical Center
Overal Status: Recruiting
Start Date: January 2014
Last Update: April 2, 2020
Lead Sponsor: Tel-Aviv Sourasky Medical Center
Brief Summary: Suicide attempts are a serious concern worldwide. Currently, existing drugs take about three weeks to show effect on suicidal thoughts and drives. Recent evidence suggests that intravenous Ketamine exerts a rapid effect in suicidal patients, even after a single injection. We aim to examine whether oral Ketamine is a safe and effective treatment in suicidal patients. Following a suicide attempt, patients will be randomized into a group that will be given Ketamine for 21 days and one that will receive placebo, and assessed using questionnaires and brain scans. We expect early improvements in suicide scales in the Ketamine group.
As a secondary goal, this study will use IV ketamine in order to access the extent to which the experience of the embodied self mediate different levels of "embodied emotion". A better understanding of these relations will assist in unveiling the cognitive mechanism underlying the therapeutic effect of ketamine
Conditions:
- Suicidal Ideation
- Major Depressive Disorder
- Healthy Participants
Total execution time in seconds: 0.24266409873962